Objective The safety of remazolam combined with sufentanil in painless endoscopic ultrasonography.
Methods Seventy-six patients with painless ultrasound gastroscopy from April 2022 to June 2022, 28 males and 48 females, aged 18-64 years, BMI 18-30 kg/m2, ASA physical status Ⅰ-Ⅲ, were selected. The patients were randomly divided into two groups using random number table method: remazolam group (group R) and propofol group (group P), 38 patients in each group. Sufentanil 0.1 μg/kg was given intravenously, 4 minutes later, remazolam 0.2 mg/kg was given intravenously in group R, and propofol 1.5 mg/kg was given intravenously in group P. When the patient's modified observer's assessment of alertness/sedation scale (MOAA/S) score ≤ 3 points, ultrasonic gastroscopy was performed. The incidence of hypotension and respiratory depression during the examination and recovery period, the sedation time, awakening time, departure time, the incidence ofsedation success, the incidence ofendoscopic success, and the incidence of adverse events such as injection pain were recorded. The satisfaction survey scores of patients, anesthesiologists, and endoscopists were recorded.
Results Compared with group P, the incidence of hypotension and respiratory depression were significantly decreased during the examination period and recovery period, and the incidence of injection pain was significantly decreased in group R (P < 0.05). There were no significant differences in sedation time, awakening time, ventricular departure time, the success rate of sedation and endoscopy, satisfaction surveys scores of patients, anesthesiologists, and endoscopists between the two groups.
Conclusion Remazolam combined with sufentanil used in painless ultrasonic gastroscopy is safe and stable in hemodynamics, with less adverse reactions in perioperative period, which can achieve sedative effect similar to propofol. |
